PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

Author's Avatar
Nov 10, 2021

PhaseBio+Pharmaceuticals%2C+Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2021 financial results.